What you will learn
By the end of this topic, you should be able to define regulatory affairs as a development function; establish product status, classification and market pathways; maintain an applicable-requirements baseline; align evidence and claims; manage interactions with authorities and conformity-assessment bodies; assemble coherent submissions; and control regulatory impact throughout the product lifecycle.
The regulatory team’s role
Regulatory affairs connects the product’s intended purpose, claims and markets with the rules and evidence needed to place and keep it on the market. Its greatest value is early: revealing pathway constraints, evidence gaps, authority expectations and change implications while the organisation can still make efficient product decisions.
Strategist
Select feasible pathways and sequence markets, evidence and authority interactions.
Interpreter
Translate law, guidance and precedent into clear development requirements.
Evidence integrator
Ensure claims, technical documentation and submissions tell one coherent story.
Lifecycle adviser
Assess changes, registrations, reporting and continued-market obligations.
Start with a stable regulatory product definition
Confirm intended purpose, indications, target population, users, use environments, operating principle, medical claims, variants, accessories, software functions and system boundary. Determine whether the product and its parts are devices, IVDs, accessories, combination products or outside medical-device scope in each market.
This work must stay connected to MTL-102 — Intended Purpose, Users and Use Environments. Small wording changes can alter classification, evidence and market route.
Create a regulatory strategy that drives the project
- Identify target markets, legal manufacturer and economic-operator model.
- Document classification and pathway rationale for each jurisdiction.
- Map standards, guidance, special controls and product-specific expectations.
- Define clinical, performance, usability, software, cybersecurity and bench evidence.
- Plan authority, notified-body and testing-laboratory interactions.
- Sequence submissions, registrations, translations and launch dependencies.
- Identify assumptions, decision dates, costs and material regulatory risks.
The strategy should be controlled and updated when claims, design, evidence, markets or external requirements change.
Maintain the applicable-requirements baseline
Track legislation, regulations, recognised or harmonised standards, common specifications, guidance, authority decisions and internal commitments. Record applicability, edition, transition date, rationale, owner and implementation evidence. Regulatory affairs should not merely distribute a list; it should work with specialists to translate requirements into actionable design inputs and lifecycle controls.
For the European product requirements model, see MTL-301 — EU MDR and IVDR General Safety and Performance Requirements.
Align evidence with claims and pathway
Regulatory should challenge claim creep and evidence gaps without designing tests alone. Work with clinical, engineering, risk, usability, quality and verification functions.
Build a submission from controlled source evidence
A submission should not become an uncontrolled second product history. Define source owners, document cut-off, review responsibilities and change handling. Check consistency across intended use, device description, variants, architecture, risk, verification, clinical evidence, labelling and declarations. Explain deviations and residual uncertainty rather than hiding contradictions.
Use MTL-113 — Design Controls and Technical Documentation for the evidence-chain foundation.
Control claims across every public and supplied-information channel
Labelling, instructions, websites, sales material, training and distributor statements must remain within the approved evidence and market status. Regulatory review should focus on substantive claims and required information, supported by clear rules and trained content owners. See MTL-128 — Labelling and Information Supplied.
Assess regulatory impact before implementing change
Evaluate intended purpose, performance, safety, software, materials, suppliers, manufacturing, labelling and cybersecurity changes against each market’s notification or submission criteria. Record the decision and rationale, including cumulative effects. Regulatory approval is one part of change control; technical verification, risk assessment, production readiness and post-market actions remain necessary.
Turn regulatory intelligence into controlled action
Monitor relevant laws, standards, guidance, authority communications and enforcement signals. Triage changes for applicability and urgency, identify affected products and processes, assign accountable owners and verify implementation. A newsletter collection is not a regulatory-intelligence system unless it drives decisions.
Common misconceptions
“Regulatory prepares the submission after development.”
Pathway and evidence decisions must shape development from the beginning.
“Using a standard guarantees approval.”
Standards support conformity; the manufacturer must still justify applicability and satisfy market-specific requirements.
“A clearance or certificate approves every future change.”
Changes require documented, jurisdiction-specific regulatory impact assessment.
Authoritative starting points
Regulatory strategy is a product-development input—not a submission-writing activity
Define the pathway and evidence expectations early, then keep claims, requirements, decisions and lifecycle changes aligned in every market.